0001209191-15-079159.txt : 20151110 0001209191-15-079159.hdr.sgml : 20151110 20151109173819 ACCESSION NUMBER: 0001209191-15-079159 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151105 FILED AS OF DATE: 20151109 DATE AS OF CHANGE: 20151109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arbuckle Stuart A CENTRAL INDEX KEY: 0001557290 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 151216901 MAIL ADDRESS: STREET 1: VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-11-05 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001557290 Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP\Chief Commercial Officer Common Stock 2015-11-05 4 M 0 5664 45.11 A 110412 D Common Stock 2015-11-05 4 M 0 600 77.31 A 111012 D Common Stock 2015-11-05 4 S 0 2444 122.46 D 108568 D Common Stock 2015-11-05 4 S 0 2400 123.04 D 106168 D Common Stock 2015-11-05 4 S 0 1220 124.59 D 104948 D Common Stock 2015-11-05 4 S 0 200 125.17 D 104748 D Common Stock 140 I 401(k) Stock Option (right to buy) 45.11 2015-11-05 4 M 0 5664 0.00 D 2023-02-04 Common Stock 5664 28320 D Stock Option (right to buy) 77.31 2015-11-05 4 M 0 600 0.00 D 2024-02-04 Common Stock 600 41900 D Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $122.46 (range $121.84 to $122.82). Open market sales reported on this line occurred at a weighted average price of $123.04 (range $122.84 to $123.60). Open market sales reported on this line occurred at a weighted average price of $124.59 (range $124.08 to $124.99). Open market sales reported on this line occurred at a weighted average price of $125.17 (range $125.13 to $125.21). The option vests in 16 quarterly installments from 02/05/2013. The option vests in 16 quarterly installments from 02/05/2014. Omar White, Attorney-In-Fact 2015-11-09